FIELD OF THE INVENTION
The invention herein is directed to chiral specific boron-containing compounds, such as boronate, boronate esters, boranamines, boranediamines, boranamine thioesters, and boronic mono/di-thioesters, as anti-cancer or anti-amyloidosis agents, as well as their compositions,
FIELD OF INVENTION
The present invention relates to oligopyridylamide alpha-helix mimetic compounds and their use for inhibiting aggregation of p53 protein to restore its tumor suppressor function for treating diseases, e.g., cancers, associated with p53 mutations, e.g., R248W p53
FIELD OF THE INVENTION
The present invention relates generally to the field of proteins associated with neural lesions. More specifically, the present invention relates to the detection of protease nexin-2 (hereinafter "PN-2") and other precursors to amyloid deposited in the
1. FIELD OF THE INVENTION
This invention relates to methods of treating, preventing and/or managing specific cancers, and other diseases including, but not limited to, those associated with, or characterized by, undesired angiogenesis, by the administration of one or more immunomodulatory compounds
TECHNICAL FIELD
The present invention relates to a fusion protein composed of a matrix metalloproteinase-2 inhibitor peptide derived from .beta.-amyloid precursor protein and a tissue inhibitor of metalloproteinase, as well as use of the fusion protein. More specifically, the present invention
TECHNICAL FIELD
The presently described subject matter relates generally to compounds that exhibit aggregation induced emission (AIE), and more particularly to water-soluble conjugated polyene compounds that exhibit aggregation induced emission. The conjugated polyene compounds can be used as
FIELD OF THE INVENTION
The presently described subject matter relates generally to compounds that exhibit aggregation induced emission, and more particularly to water-soluble conjugated polyene compounds that exhibit aggregation induced emission. The conjugated polyene compounds can be used as
1. FIELD OF THE INVENTION
This invention relates to methods of treating, preventing and/or managing specific cancers, and other diseases including, but not limited to, those associated with, or characterized by, undesired angiogenesis, by the administration of one or more immunomodulatory compounds
1. FIELD OF THE INVENTION
The present invention relates to pharmaceutical compositions that are useful for the prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer), neurodegenerative or amyloid diseases, or any other disease wherein the treatment
All patents, patent applications and publications cited herein are hereby incorporated by reference in their entirety. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to
CROSS REFERENCE TO RELATED APPLICATIONS
This application is the National Stage of International Application No. PCT/EP2015/054968, filed on Mar. 10, 2015, which claims the benefit of European Application No. 14305353.6, filed on Mar. 11, 2014. The contents of both applications are hereby
FIELD OF INVENTION
The present invention relates to the synthesis and utility of novel chemical entities with useful biochemical, physiochemical, and clinical properties. More specifically, a series of 1-alkyl, 2-acyl glycerol derivatives are provided which can be used for the treatment or
SUMMARY OF THE INVENTION
The present invention relates to an anti-dementia agent which comprises rolipram (4-[3-cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone) as an active ingredient.
As the proportion of aged people grows larger in the society, countermeasures against senile dementia causes by
All patents, patent applications and publications cited herein are hereby incorporated by reference in their entirety. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Dec. 31, 2012, is named 192408US.txt and is 31,481 bytes in size.
BACKGROUND OF THE
اكتب أحد الأعراض أو المرض واقرأ عن الأعشاب التي قد تساعد ، واكتب عشبًا واطلع على الأمراض والأعراض التي تستخدم ضدها. * تستند جميع المعلومات إلى البحوث العلمية المنشورة